Urine albumin-to-creatinine ratio testing can spot cardiovascular risk and early CKD before eGFR declines in at-risk patients, including those with type 2 diabetes, cardiovascular disease, or Hypertension (HTN). In this guideline-driven expert review, elevated ACR is described as an independent, modifiable CV risk factor that helps frontline clinicians start the right therapies earlier—exactly the kind of catch NPs and PAs are uniquely positioned to make.

Why It Matters To Your Practice

• CKD is common, under-recognized, and often silent until damage is already underway.

• Adding ACR to routine testing in at-risk patients helps you identify kidney and CV risk earlier, before creatinine or eGFR changes force the issue.

• For NPs and PAs, this is a high-value frontline move: you are often the clinician who connects diabetes, CV disease, or HTN to hidden kidney risk in real time.

Clinical Benefits

• Elevated ACR can reveal risk earlier than eGFR alone, creating a wider window for intervention.

• Earlier detection supports timely use of guideline-directed therapies aimed at slowing CKD progression and reducing CV risk.

• Routine ACR testing can strengthen risk stratification in patients with type 2 diabetes, CV disease, and HTN.

Managing Risks

• Use ACR as part of systematic screening for patients already known to be at risk for CKD.

• An abnormal result should prompt confirmation, closer follow-up, and evaluation for guideline-directed treatment opportunities.

• Because albuminuria is modifiable, identifying it early gives you a concrete target for intervention—not just another lab value.

The Bottom Line

• ACR testing helps bring hidden cardiorenal risk into view while there is still time to act.

• Nurse practitioners and physician assistants are not backup players here—you are often the first and most important clinicians to detect silent risk and move evidence-based care forward.

• Making ACR part of routine care for at-risk patients can help change the trajectory of both CKD and cardiovascular outcomes.